1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,720 | 0,915 | 26.07. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 16.07. | SOTIO partners with Biocytogen to expand ADC oncology pipeline | 2 | Pharmaceutical Technology | ||
| 16.07. | Sotio taps Biocytogen to create bispecific ADCs in $326M deal | 1 | FierceBiotech | ||
| 16.07. | SOTIO Enters into Multi-Target Antibody Agreement with Biocytogen to Expand ADC Pipeline | 170 | Business Wire | Option and license agreement includes multiple fully human bispecific antibodies generated with Biocytogen's proprietary RenLite platform Agreement will enable SOTIO to significantly broaden... ► Artikel lesen | |
| 16.07. | SOTIO Biotech: SOTIO Enters into Multi-Target Antibody Agreement with Biocytogen to Expand ADC Pipeline | 191 | Business Wire | Option and license agreement includes multiple fully human bispecific antibodies generated with Biocytogen's proprietary RenLite platform Agreement will enable SOTIO to significantly broaden... ► Artikel lesen | |
| 16.07. | BIOCYTOGEN-B (02315): VOLUNTARY ANNOUNCEMENT ENTERS INTO MULTI-TARGET ANTIBODY AGREEMENT WITH SOTIO | 2 | HKEx | ||
| 21.06. | Biocytogen Pharmaceuticals (Beijing) Co., Ltd.: Biocytogen erhält US-Patent für seine gemeinsame Leichtketten-Mausplattform RenLite | 339 | Business Wire | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) gab jetzt die Erteilung eines Patents durch das United States Patent and Trademark Office (USPTO) für die von Biocytogen... ► Artikel lesen | |
| 21.06. | Biocytogen Pharmaceuticals (Beijing) Co., Ltd.: Biocytogen Awarded U.S. Patent for RenLite Common Light Chain Mouse Platform | 239 | Business Wire | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) announced United States Patent and Trademark Office (USPTO) patent grant for independently developed RenLitefully human common... ► Artikel lesen | |
| 21.06. | BIOCYTOGEN-B (02315): VOLUNTARY ANNOUNCEMENT BIOCYTOGEN SECURES U.S. PATENT FOR RENLITE COMMON LIGHT CHAIN MOUSE PLATFORM | 2 | HKEx | ||
| 28.05. | BIOCYTOGEN-B (02315): POLL RESULTS OF THE 2023 ANNUAL GENERAL MEETING HELD ON MAY 28, 2024 | - | HKEx | ||
| 06.05. | Biocytogen Pharmaceuticals (Beijing) Co., Ltd.: Biocytogen schließt mit BioCopy eine Vereinbarung zur Evaluierung und potenziellen Lizenzierung von TCR-ähnlichen Antikörpern ab | 274 | Business Wire | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315), ein weltweit tätiges Biotechnologieunternehmen, das sich auf die Entdeckung neuartiger antikörperbasierter Therapeutika... ► Artikel lesen | |
| 06.05. | Biocytogen Pharmaceuticals (Beijing) Co., Ltd.: Biocytogen Enters Into Evaluation and Potential Licensing Agreement With BioCopy For TCR-mimic Antibodies | 234 | Business Wire | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315), a global biotechnology company focused on the discovery of novel antibody-based therapeutics, today announced a TCR-mimic... ► Artikel lesen | |
| 25.04. | BIOCYTOGEN-B (02315): FORM OF PROXY FOR THE USE AT THE 2023 ANNUAL GENERAL MEETING | - | HKEx | ||
| 25.04. | BIOCYTOGEN-B (02315): NOTICE OF THE 2023 ANNUAL GENERAL MEETING | - | HKEx | ||
| 25.04. | BIOCYTOGEN-B (02315): (1)2023 ANNUAL REPORT... (2)WORK REPORT OF BOARD (3)WORK REPORT OF SUPERVISORY COMMITTEE (4)FINAL ACCOUNTS REPORT (5)PROPOSED RE-APPOINTMENT ... | - | HKEx | ||
| 25.04. | BIOCYTOGEN-B (02315): 2023 ANNUAL REPORT | - | HKEx | ||
| 11.04. | BIOCYTOGEN-B (02315): VOLUNTARY ANNOUNCEMENT (1) UNUSUAL PRICE MOVEMENT; AND (2) SHARE PURCHASE BY TRUSTEE PURSUANT TO SHARE AWARD SCHEME | 1 | HKEx | ||
| 27.03. | BIOCYTOGEN-B (02315): ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2023 | 2 | HKEx | ||
| 25.03. | Biocytogen Pharmaceuticals (Beijing) Co., Ltd.: Biocytogen schließt Kooperation mit ABL Bio, um neue bispezifische Antikörper-Wirkstoff-Konjugate zu entwickeln | 239 | Business Wire | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315), ein weltweit tätiges Biotechnologieunternehmen, das sich auf die Entwicklung neuartiger Antikörpertherapeutika konzentriert... ► Artikel lesen | |
| 25.03. | Biocytogen Pharmaceuticals (Beijing) Co., Ltd.: Biocytogen Enters Collaboration with ABL Bio to Develop New Bispecific Antibody-Drug Conjugates | 252 | Business Wire | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies... ► Artikel lesen | |
| 15.03. | BIOCYTOGEN-B (02315): DATE OF BOARD MEETING | 1 | HKEx |
Seite:
1 2 Weiter >>
38 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MEDIGENE | 1,135 | -1,30 % | PTA-News: Medigene AG: Medigene präsentiert auf dem ESMO-Kongress 2024 | DJ PTA-News: Medigene AG: Medigene präsentiert auf dem ESMO-Kongress 2024
Unternehmensmitteilung für den Kapitalmarkt
Planegg/Martinsried (pta/23.07.2024/11:15) - Die Medigene AG ( http://www.medigene.de... ► Artikel lesen | |
| BIOFRONTERA | 2,375 | +2,59 % | PTA-Adhoc: Biofrontera AG: Rechtsstreit um Import in die USA und daraus resultierende Prognose | DJ PTA-Adhoc: Biofrontera AG: Rechtsstreit um Import in die USA und daraus resultierende Prognose
Veröffentlichung von Insiderinformationen gemäß Artikel 17 MAR
Leverkusen (pta/21.07.2024/14:45)... ► Artikel lesen | |
| CLINUVEL | 9,045 | -0,44 % | Clinuvel Pharmaceuticals Limited: Photomedicine Pioneer CLINUVEL Unveils Clinical, Cosmetic Ambitions to German Investors | DÜSSELDORF, Germany, March 28, 2024 (GLOBE NEWSWIRE) -- Pioneering biopharmaceutical company CLINUVEL yesterday hosted a wide-ranging market briefing discussing its novel drug SCENESSE® (afamelanotide)... ► Artikel lesen | |
| EDITAS MEDICINE | 5,322 | +2,35 % | Editas Medicine, Inc.: Editas Medicine Announces New Safety and Efficacy Data from the EdiTHAL Trial of Reni-cel in 7 Patients with Transfusion-dependent Beta Thalassemia, Presented at the European Hematology Association (EHA) Annual Congress | All patients treated in the EdiTHAL trial maintained hemoglobin levels above the transfusion threshold and are transfusion-free post-renizgamglogene autogedtemcel (reni-cel) infusion Reni-cel was... ► Artikel lesen | |
| BLUEBIRD BIO | 1,129 | +0,89 % | HHS gives thumbs down to bluebird's fertility support programme | ||
| ASEP MEDICAL | 0,069 | -9,92 % | Asep Medical bestätigt, dass der Einsatz von KI verbesserte Behandlungen der häufigen Biofilminfektionen und eine schnelle Sepsisdiagnose ermöglicht | VANCOUVER, BC, 13. März 2024 - In seiner jüngsten Präsentation vor der US-amerikanischen Biophysical Society in Philadelphia1 berichtete Dr. Bob Hancock, CEO von Asep Medical Holdings... ► Artikel lesen | |
| BELLEROPHON THERAPEUTICS | 0,001 | 0,00 % | Bellerophon Therapeutics, Inc. - 15-12G, Securities registration termination | ||
| CARDIFF ONCOLOGY | 2,200 | +1,85 % | Cardiff Oncology, Inc.: Cardiff Oncology Presents Novel Preclinical Data at AACR Annual Meeting 2024 that Supports Ongoing First-line RAS-mutated mCRC Clinical Study | RAS-mutated mCRC - In RAS-mutated mCRC, novel preclinical finding demonstrates onvansertib inhibits the tumor's ability to adapt to hypoxia resulting in a significant decrease in both tumor vascularization... ► Artikel lesen | |
| CELLECTAR BIOSCIENCES | 2,100 | 0,00 % | Pre-market Movers: Frequency Electronics, Mammoth Energy Services, MIRA Pharmaceuticals, Cellectar Biosciences, Polaris Inc. | SANDY SPRINGS (dpa-AFX) - The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 07.40 A.M. ET).In the Green Frequency Electronics, Inc. (FEIM) is up over... ► Artikel lesen | |
| FRESH TRACKS THERAPEUTICS | 0,730 | 0,00 % | Fresh Tracks Therapeutics, Inc.: Fresh Tracks Therapeutics Urges Stockholders to Vote at the Upcoming Special Meeting on February 15th | Stockholders of record on January 11, 2024 who have not yet voted are encouraged to do so by 11:59 p.m. Eastern Time on February 14, 2024 BOULDER, Colo., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Fresh Tracks... ► Artikel lesen | |
| CLEAN HARBORS | 207,40 | +0,63 % | Peering Into Clean Harbors' Recent Short Interest | ||
| MESOBLAST | 0,715 | +5,15 % | Mesoblast Limited: FDA Accepts Mesoblast's Biologics License Application (BLA) for Ryoncil in Children With Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD) | NEW YORK, July 23, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced that the United States Food... ► Artikel lesen | |
| SPERO THERAPEUTICS | 1,286 | -2,72 % | Spero Therapeutics, Inc.: Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | CAMBRIDGE, Mass., July 03, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments... ► Artikel lesen | |
| CSTONE PHARMACEUTICALS | 0,137 | -3,52 % | CStone Announces European Commission Approval of Sugemalimab (Cejemly®) as First-Line Treatment for Non-Small Cell Lung Cancer | Sugemalimab becomes the world's first anti-PD-L1 monoclonal antibody (mAb) approved in Europe for first-line treatment of both squamous and non-squamous non-small cell lung cancer (NSCLC)... ► Artikel lesen | |
| PROTALIX BIOTHERAPEUTICS | 1,046 | -0,90 % | Protalix BioTherapeutics Inc. Q1 Loss Increases, Misses Estimates | JERUSALEM (dpa-AFX) - Protalix BioTherapeutics Inc. (PLX) released Loss for its first quarter that increased from last year and missed the Street estimates.The company's earnings came in at... ► Artikel lesen |
BIOCYTOGEN PHARMACEUTICALS BEIJING CO LTD gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von -0,025 (-3,42 %) liegt der Kurs bei 0,705 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIOCYTOGEN PHARMACEUTICALS BEIJING CO LTD finden Sie auf Wallstreet Online.
